Objective: One of the rate-limiting barriers within the field of vascular tissue engineering is the lengthy fabrication time associated with expanding appropriate cell types in culture. One particularly attractive cell type for this purpose is the adipose-derived mesenchymal stem cell (AD-MSC), which is abundant and easily harvested from liposuction procedures. Even this cell type has its drawbacks, however, including the required culture period for expansion, which could pose risks of cellular transformation or contamination. Eliminating culture entirely would be ideal to avoid these concerns. In this study, we used the raw population of cells obtained after digestion of human liposuction aspirates, known as the stromal vascular fraction (SVF), as an abundant, culture-free cell source for tissue-engineered vascular grafts (TEVGs).
Tissue engineers have developed small-diameter (<6 mm) vascular grafts that possess reduced intimal hyperplasia and thrombosis compared with current clinical standards, representing excellent progress toward clinical application. [1] [2] [3] [4] [5] However, despite the significant degree of preclinical testing that cell-based tissue-engineered vascular grafts (TEVGs) have undergone, 3 few approaches have reached clinical trials. [6] [7] [8] This is likely attributed to a number of practical rate-limiting barriers still present that hinder the clinical translation of TEVGs, including appropriate testing of patient-specific cells (eg, clinically appropriate demographics), 9 lack of feasible and consistent modes of manufacture to appropriate sizes, the need for culture expansion of cells to a suitable number, and lengthy fabrication time. 10 Although the first two of these concerns have been validated in recent years, 3, 9 the necessity of in vitro culture and lengthy fabrication times that are used by many TEVG designs 3 are still major concerns.
Specific concerns for clinical application include excess waiting time for the patient, significant costs, such as cell culture reagents and personnel, and potential cellular transformation or contamination.
To successfully translate cell-based TEVGs to the clinic, identifying a tissue source that can provide a high number of quality cells in the shortest amount of time is important. One of the most attractive tissues for this purpose is fat, which can be obtained in abundance from liposuction procedures and provides human adipose-derived mesenchymal stem cells (AD-MSCs). However, even AD-MSCs require time for vitro expansion into necessary numbers. 11 Alternatively, the digested liposuction population of cells used to obtain AD-MSCs, known as the stromal vascular fraction (SVF), could be used because it is progenitor rich, containing AD-MSCs, pericytes, endothelial progenitor cells, and endothelial cells. 12 Because all of these cell types have been successfully used in vascular tissue engineering, 3 the SVF could hold significant promise as a cell source. In addition, typical liposuction volumes are sufficient to obtain large enough quantities of cells for the construction of a graft of clinically relevant dimensions without additional in vitro expansion. 13, 14 Using the SVF to seed scaffolds for vascular tissue engineering could therefore be ideal for the clinical translation of TEVGs, relieve many regulatory and financial concerns, and make a significant step forward in the fabrication of stem cell-based TEVGs.
In this study, the use of the human SVF was validated for vascular tissue engineering using in vitro and in vivo studies. This initial small-scale study showed that the SVF can be used to produce rapidly fabricated TEVGs with robust in vivo performance functionally similar to TEVGs composed of culture expanded AD-MSCs generated from the same human donors.
METHODS
Isolation of human SVF and AD-MSCs. AD cell fractions were isolated, using previously described methods, from nondiabetic patients undergoing liposuction. 12, 15 The
University of Pittsburgh Institutional Review Board determined that informed consent was not required because the study only used deidentified waste from the liposuction procedure. Under this type of protocol determination, only the presented information (age, gender, body mass index, and diabetic status) could be provided (Table) . Liposuction yields were on the order of several kilograms, from which 200 mL was removed and dissociated by mincing and digestion with collagenase. The resulting solution was filtered to remove debris, centrifuged to eliminate buoyant adipocytes, resuspended in an erythrocyte lysis buffer to eliminate red blood cells, and centrifuged to obtain a final cell pellet. A typical cell yield from this procedure was 30 to 40 million cells. These cells will be referred to in this report as the SVF.
For this study, a cultured AD-MSC control was established from each SVF donor by passage expanding a portion of the SVF four times. 9, 15 By using this procedure, the SVF was available for graft fabrication within a matter of hours, whereas AD-MSCs took upwards of 4 weeks. marker smooth muscle a-actin is ubiquitously expressed in AD-MSCs before differentiation. Donor-paired cultured AD-MSCs were used as a positive control for differentiation, and the nonstimulated SVF was used as a negative control. Differentiation was assessed by calponin expression and a morphologic shift to a typical SMC spindle-like shape. Quantification of this morphologic shift was obtained by measuring each cell's shape factor (shape factor ¼ 4 Â p Â [area/perimeter 2 ]), w0 ¼ ellipsoid, w1 ¼ circular, wherein differentiation is reflected by conversion from a round (nearer to 1) to spindle-like (nearer to 0) shape.
Stimulation of SMC migration also was performed using previous protocols. 15 Briefly, SMCs were plated near confluence in a 24-well plate, and a scratch wound was made by a single stroke of a pipette tip per well. During migration, SMCs were stimulated with conditioned media from the SVF, donor-matched AD-MSCs, or nonconditioned media. All cells were maintained under culture conditions (37 C, 5% CO 2 ) for the duration of the experiment. The extent of migration was monitored every 2 hours and reported as the average rate of scratch wound closure over the first 8 hours. Three donor lines were used in these studies (Table) .
Scaffold fabrication. Small (1.3-mm internal diameter, 10-mm length) bilayered, tubular, biodegradable, elastomeric scaffolds consistent with the size of the rat abdominal aorta were constructed from poly(ester urethane)urea, as previously described. 22 Briefly, a porous inner layer was created by thermally induced phase separation, which was then coated with an external mechanical sheath by electrospinning. This scaffold has already shown efficacy in the TEVG context using multiple cell types. 1, 4, 9, 23 Cell seeding. A rotational vacuum seeding device technology was used to seed poly(ester urethane)urea scaffolds as previously described. 1, 4, 23, 24 Briefly, scaffolds were mounted within the device, infused lumenally with a cell suspension, and exposed to rotation (15 rpm) and vacuum (À127 mm Hg). This process was used to incorporate 3 million cells (SVF or donor-matched AD-MSCs) within each scaffold. After seeding, the resulting constructs were incubated in static media for 4 hours to allow for cell adhesion, after which they were subjected to a dynamic culture (spinner flask, 15 rpm) for 48 hours which primed them for seeding analysis or implantation. For analysis of uniform seeding, constructs were fixed for 30 minutes in 4% paraformaldehyde, cut into three axial portions, and frozen. Scaffolds were then sectioned and stained with 4 0 ,6-diamidino-2-phenylindole to analyze the cell distribution. Images were acquired at original magnification Â10 using Elements software (National Institutes of Health, Bethesda, Md) and analyzed using custom scripts built within ImageJ software (National Institutes of Health). 9 This generated complete crosssectional images, virtually segmented into radial or circumferential pieces, and cell densities were compared with respect to radial, circumferential, or longitudinal pieces.
In vivo implantation and explant. All animal procedures were performed under a protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Seeded scaffolds were implanted as end-to-end abdominal aortic grafts in our Lewis rat model. 1, 4, 9, 23 The four patients noted in the Table under "Human donors used for differentiation, migration, and implantation experiments" were used as the source of cells to produce, with some replicates, six SVF and five AD-MSC grafts for implantation.
Rats were anesthetized, and the infrarenal abdominal aorta was exposed. Microclamps were applied to the aorta before transection, upon which a seeded scaffold was sutured with 10-0 Prolene (Ethicon, Somerville, NJ). After the graft was secured, the clamps were released and the patency verified by observation of the distal pulse pressure. The animals were then closed with 3-0 polyglactin sutures and maintained on an anticoagulant (dipyridamole, aspirin) schedule for 4 weeks, as previously described. 9 After 8 weeks, the rats were euthanized, and an angiogram was performed to assess TEVG patency. TEVGs were then explanted, fixed, and frozen for histologic analysis.
Immunofluorescence and histologic evaluation. Frozen TEVGs were sectioned using a cryomicrotome at an 8-mm thickness, mounted on gelatin-coated slides, and stained using standard indirect immunofluorescent chemistry. Primary antibodies used were von Willebrand factor (1:250; #V2700-07, United States Biological, Salem, Mass), smooth muscle a-actin (1:1000, #A5228; SigmaAldrich, St. Louis, Mo), calponin (1:250, #ab46794; Abcam, Cambridge, Mass), and elastin (1:100, #RA75; Elastin Products Company, Inc, Owensville, Mo). The following secondary antibodies were used: FITC-conjugated goat anti-rabbit IgG (1:1000, #611-1202; Rockland, Limerick, Pa), Cy3-conjugated goat anti-mouse IgG (1:1000, #A10521; Invitrogen, Carlsbad, Calif), and Cy3-conjugated rabbit anti-goat IgG (1:300, #C2821; Sigma-Aldrich).
Explants were also stained with hematoxylin and eosin. All images were taken at original magnification Â 20 with an epifluorescent microscope using Elements software. Analysis was restricted to the newly developed luminal tissue within TEVGs (termed as "neotissue").
Statistics. Statistical analyses were performed in Minitab 16 software (Minitab Inc, State College, Pa). Data were first assessed for assumptions of a normal distribution and homogeneity of variance. After this, a Student t-test was performed with significance defined at P < .05. Continuous data are reported as mean 6 standard deviation.
RESULTS
Human SVF cells differentiated into SMC-like cells and secreted factors to promote SMC migration. To initially investigate the relevance of SVF cells for TEVG applications, the abilities of SVF cells to differentiate into SMCs and to induce SMC migration were analyzed. Both of these stem cell functions are important for achieving maturation of a TEVG into a native-like vessel. 15 Donormatched AD-MSCsda cell population previously validated in this manner 15 dand SVF cells both underwent differentiation into SMC-like cells and secreted factors to promote SMC migration. For SMC differentiation, this was shown by induced expression of the SMC marker calponin ( Supplementary Fig, A, online only) and a morphologic change to a more spindle-like cell shape (eg, a decreased shape factor; Supplementary Fig, B , online only). Even though the broad percentage of differentiated cells was low, discernible donor Human stromal vascular fraction (SVF) can be seeded uniformly within porous tubular scaffolds and generate patent vessels to a similar extent as adipose-derived mesenchymal stem cells (AD-MSCs). A, SVF (n ¼ 3) was obtained from patients and seeded directly into poly(ester urethane)urea scaffolds where they seeded uniformly (blue; 4 0 ,6-diamidino-2-phenylindole stain) throughout the thickness of the scaffold wall. A representative image is shown. B, This uniformity was quantitatively confirmed by comparing radial distribution densities of cells across three radial regions, which each contained w33% of the total cells. This is in line with our previous work quantitatively showing uniformity of scaffolds seeded with AD-MSCs. 13 Data are presented as mean 6 standard deviation (range bars) with a statistically significant difference defined at P < .05. C, The SVF and donor-matched AD-MSCs were both capable of generating patent tissue-engineered vascular grafts (TEVGs) based on patency rates. D, Seeded scaffolds with SVF or donor-matched AD-MSCs were implanted in a Lewis rat model in which they maintained angiographic patency through a period of 8 weeks. The TEVG location is indicated. E, All explanted TEVGs displayed a clear tissue-like gross appearance, compared with the unremodeled poly(ester urethane)urea scaffold. differences can be detected with this assay. 15 The ability of both AD-MSCs and SVF cells to promote migration of SMCs was evident by the significant increase in the migration rate observed in SMCs when stimulated with conditioned media from either cell type ( Supplementary  Fig, C , online only). Taken together, these results verify that the SVF has functions present in AD-MSCs necessary for TEVG maturation and thus can be used in the context of vascular tissue engineering.
Human SVF cells were able to be seeded within tissueengineered scaffolds and generated robust, patent vessels in vivo. To verify that SVF cells could be seeded within our porous tubular scaffolds and as a point of quality control, the extent to which SVF was incorporated within our scaffolds using our rotational vacuum seeding device was quantified. The SVF was evenly seeded throughout the scaffolds in cross section (Fig 1, A) , and equivalent cell densities were observed across the radial, circumferential, and longitudinal directions (Fig 1, B, radial  shown) . This is in line with previously published work analyzing scaffolds seeded with AD-MSCs. 9 The SVF-seeded scaffolds were implanted in a Lewis rat model, where after 8 weeks in vivo, they remained patent, as confirmed by angiography, similar to their counterpart AD-MSC grafts (Fig 1, C and D) . No dilation was observed for any implanted vessel. On gross observation, TEVGs generated from the SVF or AD-MSCs showed an evident tissue-like appearance (Fig 1, E) . Together these results show that the SVF and AD-MSCs are both capable of generating patent, tissue-like TEVGs.
The SVF develops vascular-like tissue within TEVGs that is rich in primary vascular components. To analyze the composition of the newly developed tissue within the TEVGs, the primary cellular (SMCs, endothelial cells), and extracellular (elastin, collagen) vascular components were detected using multiple imaging modalities. Immunofluorescence (Fig 2) revealed that the cellular components of the explanted TEVGs, either SVF or AD-MSCs, primarily consisted of SMCs (smooth muscle a-actin and calponin labeling) with a luminal lining of endothelial cells (von Willebrand factor labeling). Immunofluorescence also confirmed the presence of elastin in both SVF-based and AD-MSC-based TEVGs; however, it had not yet formed into fully developed elastic lamellae. Finally, multiphoton microscopy was used to detect the presence of the extracellular matrix component collagen within explanted TEVGs. This imaging modality revealed prominent, circumferentially For comparison, native artery images are included from Krawiec et al. 9 Scale bar = 100 mm.
aligned collagen fibers within all TEVGs explants (Fig 2) . Taken together, these results show that when the SVF is used as the cell source for TEVGs, a vascular-like composition emerges similar to that observed with donor-matched AD-MSCs.
DISCUSSION
The results of this study show that the SVF can perform the same functions as paired AD-MSCs derived from the same donor for use in a TEVG. First, the SVF was capable of two stem cell-based bioactivities thought to be of possible importance in vascular tissue engineering: differentiation into vascular SMCs 3,15-18 and secretion of promigratory factors 2, 15, [19] [20] [21] ( Supplementary Fig, online only). Second, the SVF cells were shown to be incorporated within porous tubular, biodegradable, elastomeric scaffolds and generate patent TEVGs (Fig 1) with vascular-like tissue after implantation (Fig 2) . The results of this study indicate the functional efficacy of a freshly isolated noncultured AD cell source in the context of vascular tissue engineering, is favorably comparable to published work with cultured AD-MSCs. 9 Ultimately, the use of this cell source reduces rate-limiting barriers that could hinder the clinical translation of TEVGs. Indeed, the SVF has previously been shown to perform the same functions as AD-MSCs in other applications, 25, 26 such as Crohn disease and myocardial infarction, which has supported the use of the SVF in multiple clinical trials. [27] [28] [29] Although noncultured bone marrow cells have already been used as a noncultured cell source for vascular tissue engineering and can generate an equally sizable number of cells 30 as adipose tissue 13, 14 (on the order of millions per mL), the use of an AD cell source confers unique benefits. In addition to the aesthetic attractiveness of harvesting adipose tissue to obtain the SVF, performing a liposuction on a patient is associated with a reduction in cardiovascular disease risk factors. 31 The Food and Drug Administration also encourages controllable methods 33, 35 of manufacture that can be accomplished with cell-processing devices. Using our automated bulk cell-seeding device in conjunction with the SVF makes a significant practical step in the design and fabrication of stem cell-based TEVGs. However, manual methods and xenogenic enzymes are still required to isolate these cells. 11, 12, 15 Automated technologies 36 are currently being tested to alleviate these concerns, and technologies that can isolate the SVF without enzymes are also being considered. 37 It is foreseeable that with the combination of these technologies, the SVF, and our cell-seeding methods, a TEVG could be fabricated at the bedside and within the same surgical procedure. Although this study acts as a small-scale feasibility investigation of the use of culture-free AD cells (eg, SVF) to enhance and improve on TEVG fabrication methods, many unaddressed areas still require further investigation. Specifically, multiple questions remain unanswered, such as:
d What are the phenotypic differences between the SVF and AD-MSCs? d How do these differences contribute to the overall maturation of TEVGs in vivo? d What are the long-term outcomes of these grafts (eg, at time points >8 weeks)?
Each of these areas are of current interest for future study; for example, the proelastogenic effect of AD-MSCs is relevant to another vascular context, abdominal aortic aneurysm. 38 In addition, although this proofof-concept study was performed with immunotolerant rats implanted with human cells, large-scale studies will need to be performed to fully understand how this graft will function in models with more similar biology and geometry to that of humans.
CONCLUSIONS
A noncultured human cell source (ie, SVF) can be isolated from adipose tissue and used in vascular tissue engineering similarly to donor-matched cultureexpanded AD-MSCs. These cells are capable of essential regenerative functions, can be effectively bulk seeded using a controllable device, and can generate TEVGs
